Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer

Intern Med. 2019;58(5):699-702. doi: 10.2169/internalmedicine.1001-18. Epub 2019 Mar 1.

Abstract

We herein report a 78-year old man with squamous cell carcinoma of the lungs treated with pembrolizumab. At 10 days after the administration of pembrolizumab, he showed progressive anemia and increased levels of bilirubin. Because the findings of a direct coombs test and cold hemagglutinin were positive, we diagnosed the patient with autoimmune hemolytic anemia and treated him with prednisolone. Subsequently, he was admitted to our hospital owing to fatigue, a high fever, and jaundice. His clinical findings met the diagnostic criteria of hemophagocytic lymphohistiocytosis, and he was rescued with a high dose of glucocorticoids. Marked tumor regression was obtained and has been maintained since then.

Keywords: autoimmune hemolytic anemia; hemophagocytic lymphohistiocytosis; immune checkpoint inhibitors; non-small cell lung cancer; pembrolizumab.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Anemia, Hemolytic, Autoimmune / etiology
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Squamous Cell / drug therapy*
  • Coombs Test
  • Glucocorticoids / therapeutic use
  • Humans
  • Jaundice / drug therapy
  • Jaundice / etiology
  • Lung Neoplasms / drug therapy*
  • Lymphohistiocytosis, Hemophagocytic / drug therapy*
  • Lymphohistiocytosis, Hemophagocytic / etiology
  • Male
  • Prednisolone / therapeutic use
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Prednisolone
  • pembrolizumab